Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Shattuck Labs Inc
STTK | US
6.92
USD-0.48
-6.49%
STTK | US
About Shattuck Labs Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
6.92
Open
7.39
High
7.45
Low
6.84
Shattuck Labs Inc. a clinical-stage biotechnology company develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154 which is in Phase 1 clinical trial for the treatment of ovarian fallopian tube and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin Texas.
View LessSTTK | US
Risk
55.5
Sharpe
6.18
Luna's Score
60/100
Recommendation
Hold
Luna says (STTK | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
75.6%1 month
55.5%3 months
70.4%6 months
81.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.60
Debt to equity
0.03
Debt to assets
0.03
Ent. to EBITDA
-3.62
Ent. to rev.
18.32
PEG
-
Other Fundamentals
EBITDA
-86.32M
MarketCap
330.27M
MarketCap(USD)
330.27M
Div. yield
-
Op. margin
-1.43K
Erngs. growth
-
Rev. growth
704.50
Ret. on equity
-68.48
Short ratio
37.02
Short perc.
17.17
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.75
Range1M
2.12
Range3M
4.16
Volumes: Market Activity
Rel. volume
0.83
Price X volume
3.22M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.62 | - | Cheaper |
| Ent. to Revenue | 18.32 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.60 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 70.43 | - | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 330.27M | - | Emerging |
